Surveillance of gonococcal antimicrobial susceptibility resulting in early detection of emerging resistance

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 6, 2012, Pages 1422-1426

  Lo, Janice Yee Chi ^a   Ho, King Man ^a   Lo, Angus Chun Tim ^a  

^a DEPARTMENT OF HEALTH   (Hong Kong)

Author keywords

Cephalosporins; Neisseria gonorrhoeae; Surveillance; Treatment failure

Indexed keywords

AZITHROMYCIN; BETA LACTAMASE; CEFTIBUTEN; CEFTRIAXONE; DOXYCYCLINE; SPECTINOMYCIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BIOSURVEILLANCE; ENZYME ACTIVITY; FOLLOW UP; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NONHUMAN; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMS; DRUG RESISTANCE, BACTERIAL; FEMALE; GONORRHEA; HONG KONG; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MOLECULAR TYPING; NEISSERIA GONORRHOEAE; SEQUENCE ANALYSIS, DNA; SPECTINOMYCIN;

EID: 84861116980     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks036     Document Type: Article

References (26)

1. CDC. Sexually transmitted diseases treatment guidelines. MMWR Morb Mortal Wkly Rep 2006; 55 (No. RR-11): 1-100.
2. Tapsall J. Antibiotic Resistance in Neisseria gonorrhoeae. WHO, Geneva, Switzerland. WHO/CDS/CSR/DRS/2001.3, 2001. http://www.who.int/csr/resources/publications/drugresist/Neisseria_gonorrhoeae.pdf (17 January 2012, date last accessed).
3. Tapsall JW. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis 2009; 22: 87-91.
4. CDC. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007; 56: 332-6.
5. Bignell C. 2009 European (IUSTI/WHO) guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2009; 20: 453-7.
6. Ameyama S, Onodera S, Takahata M et al. Mosaic-like structure of penicillin-binding protein 2 gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob Agents Chemother 2002; 46: 3744-9.
7. Deguchi T, Yasuda M, Yokoi S et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother 2003; 9: 35-9.
8. Yokoi S, Deguchi T, Ozawa T et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007; 13: 1275-7.
9. Lo JY, Ho KM, Leung AO et al. Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. Antimicrob Agents Chemother 2008; 52: 3564-7.
10. WHO Western Pacific Region. WHO Warns of Danger of Untreatable Gonorrhoea. Press release 29 April 2010. http://www.wpro.who.int/media_centre/press_releases/pr_20100429.htm (2 December 2011, date last accessed).
11. Ohnishi M, Golparian D, Shimuta K et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011; 55: 3538-45.
12. WHO Collaborating Centre for STD, Sydney. Surveillance Standards for Gonococcal Antimicrobial Resistance. Document: D007-0408-1#1, 2009.
13. Tapsall JW. Antibiotic resistance in Neisseria gonorrhoeae. Clin Infect Dis 2005; 41 Suppl 4: S263-8.
14. Chong LY, Cheung WM, Leung CS et al. Clinical evaluation of ceftibuten in gonorrhea: a pilot study in Hong Kong. Sex Transm Dis 1998; 25: 464-7.
15. WHO Western Pacific and South East Asian Gonococcal Antimicrobial Surveillance Programmes. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific and South East Asian Regions, 2009. Commun Dis Intell 2008; 35: 2-7.
16. Ho KM, Lo JY, Lo AC et al. Evaluation of replacing the existing diagnostic strategy for Neisseria gonorrhoeae and Chlamydia trachomatis infections with sole molecular testing of urine specimens in a sexually transmitted infection clinic setting. Sex Transm Infect 2009; 85: 322-5.
17. WHO. Laboratory Diagnosis of Gonorrhoea. WHO Regional Publications, South-East Asia Series, No. 33. Regional Office for South-East Asia, 1999.
18. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-first Informational Supplement M100-S21. CLSI, Wayne, PA, USA, 2011.
19. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 2.0. 2012. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v_2.0_120101.pdf (17 January 2012, date last accessed).
20. Unemo M, Fasth O, Fredlund H et al. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother 2009; 63: 1142-51.
21. Takahata S, Senju N, Osaki Y et al. Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 2006; 50: 3638-45.
22. Lee SG, Lee H, Jeong SH et al. Various penA mutations together with mtrR, porB and ponA mutations in Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone. J Antimicrob Chemother 2010; 65: 669-75.
23. Allen VG, Farrell DJ, Rebbapragada A et al. Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada. Antimicrob Agents Chemother 2011; 55: 703-12.
24. Martin IM, Ison CA, Aanensen DM et al. Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area. J Infect Dis 2004; 189: 1497-505.
25. Tapsall JW, Ndowa F, Lewis DA et al. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009; 7: 821-34.
26. Lindberg R, Fredlund H, Nicholas R et al. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porbIb, and ponA. Antimicrob Agents Chemother 2007; 51: 2117-22.